Literature DB >> 9791037

Measurement and significance of circulating natriuretic peptides in cardiovascular disease.

G A Sagnella1.   

Abstract

1. The major cardiovascular and renal actions of alpha-atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) and the fact that the heart is strategically located to sense changes in intravascular volume indicate the importance of these peptides in the overall control of the extracellular fluid volume under normal and pathophysiological conditions.2. This review examines the clinical and diagnostic significance of the measurement of plasma natriuretic peptides in diseases of the cardiovascular system with particular emphasis on the assessment of patients with heart failure. 3. Raised plasma levels of ANP and BNP have repeatedly been found in patients with heart disease originating from diverse causes including tachycardias, valvular stenosis or ventricular dysfunction. The raised circulating levels of natriuretic peptide (ANP, N-terminal proANP and BNP in particular) are associated with (i) raised atrial and pulmonary wedge pressures; (ii) reduced ventricular systolic and diastolic function; (iii) presence (and possibly geometric form) of left ventricular hypertrophy; and (iv) severe myocardial infarction. Although both plasma ANP and BNP are raised in the presence of left ventricular hypertrophy, BNP appears to be a better index of left ventricular hypertrophy.4. Several situations where the measurement of natriuretic peptides may be of benefit in the overall assessment of heart disease are discussed. However, it is emphasized that the measurement of plasma natriuretic peptides alone appears to be of limited value as a specific diagnostic tool, given that raised levels are a consequence of haemodynamic and structural abnormalities arising from diverse pathological processes. Despite these limitations, the major value of plasma natriuretic peptides in the examination of patients with suspected heart disease rests on the premise that: (i) a normal value would not be consistent with cardiac disease; (ii) the presence of markedly raised levels may help to target those for subsequent detailed assessment of underlying cardiac dysfunction; and (iii) markedly raised levels of plasma natriuretic peptides after myocardial infarction can identify those at high risk of death.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9791037     DOI: 10.1042/cs0950519

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  25 in total

1.  Possibility of age regulation of the natriuretic peptide C-receptor in human platelets.

Authors:  D Giannessi; M G Andreassi; S Del Ry; A Clerico; M G Colombo; N Dini
Journal:  J Endocrinol Invest       Date:  2001-01       Impact factor: 4.256

Review 2.  Screening for left ventricular dysfunction: a step too far?

Authors:  T A McDonagh
Journal:  Heart       Date:  2002-10       Impact factor: 5.994

3.  Management of diastolic heart failure in older adults: B-type natriuretic peptide was not mentioned.

Authors:  Kieran M Walsh
Journal:  BMJ       Date:  2004-06-05

4.  Brain natriuretic peptide is a potentially useful screening tool for the detection of cardiovascular disease in patients with rheumatoid arthritis.

Authors:  S M J Harney; J Timperley; C Daly; A Harin; T James; M A Brown; A P Banning; K Fox; S Donnelly; B P Wordsworth
Journal:  Ann Rheum Dis       Date:  2006-01       Impact factor: 19.103

5.  Localization profiles of natriuretic peptides in hearts of pre-hibernating and hibernating Anatolian ground squirrels (Spermophilus xanthoprymnus).

Authors:  Mustafa Öztop; Mehmet Özbek; Narin Liman; Feyzullah Beyaz; Emel Ergün; Levent Ergün
Journal:  Vet Res Commun       Date:  2019-01-28       Impact factor: 2.459

6.  Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice.

Authors:  J W Knowles; G Esposito; L Mao; J R Hagaman; J E Fox; O Smithies; H A Rockman; N Maeda
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

7.  AlphaANP, AVP, and pituitary-thyroid axis in patients with congestive heart failure and acute respiratory failure.

Authors:  S Savastano; V Cannavale; R Valentino; A P Tommaselli; R Rossi; A Luciano; L Tauchmanovà; A Mariano; L Mazzitelli; V Macchia; G Lombardi
Journal:  J Endocrinol Invest       Date:  1999-11       Impact factor: 4.256

8.  Clinical relevance of cardiac natriuretic peptides measured by means of competitive and non-competitive immunoassay methods in patients with renal failure on chronic hemodialysis.

Authors:  A Clerico; R Caprioli; S Del Ry; D Giannessi
Journal:  J Endocrinol Invest       Date:  2001-01       Impact factor: 4.256

Review 9.  B-type natriuretic peptide: physiologic role and assay characteristics.

Authors:  Hassan M E Azzazy; Robert H Christenson
Journal:  Heart Fail Rev       Date:  2003-10       Impact factor: 4.214

10.  Cardiac toxicity of high-dose cyclophosphamide in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation.

Authors:  Samo Zver; Vesna Zadnik; Matjaz Bunc; Polona Rogel; Peter Cernelc; Mirta Kozelj
Journal:  Int J Hematol       Date:  2007-06       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.